AF-228-NA

antibody from R&D Systems

Targeting: IL6ST CD130, GP130, sGP130

Western blot (Data presented on provider website)

Blocking/Neutralizing (Supportive data in Antibodypedia)

Antibody Data

Product number

AF-228-NA

Provider

R&D Systems

Product name

Human gp130 Antibody

Antibody type

Polyclonal

Description

Immunogen affinity purified. Detects human gp130 in direct ELISAs and Western blots. In direct ELISAs, less than 2% cross-reactivity with recombinant rat gp130, recombinant mouse gp130, recombinant human (rh) IL-1 sRI, rhIL-1 sRII, rhIL-2 sR beta , rhIL-2 sR gamma , rhIL-4 sR, and rhIL-6 sR is observed.

Reactivity

Human

Host

Goat

Conjugate

Unconjugated

Antigen sequence

P40189


Isotype

IgG

Vial size

100 ug

Concentration

LYOPH

Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.

References

Submitted references

NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma.

McFarland BC, Hong SW, Rajbhandari R, Twitty GB Jr, Gray GK, Yu H, Benveniste EN, Nozell SE
PloS one 2013;8(11):e78728

---

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG
Nature genetics 2012 Jul 1;44(8):852-60

---

Disturbances in the LIF pathway in the endometrium among women with unexplained infertility.

Aghajanova L, Altmäe S, Bjuresten K, Hovatta O, Landgren BM, Stavreus-Evers A
Fertility and sterility 2009 Jun;91(6):2602-10

---

Expression of leukemia inhibitory factor and its receptors is increased during differentiation of human embryonic stem cells.

Aghajanova L, Skottman H, Strömberg AM, Inzunza J, Lahesmaa R, Hovatta O
Fertility and sterility 2006 Oct;86(4 Suppl):1193-209

---

Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.

Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL
Cancer research 2005 Oct 1;65(19):8896-904

---

The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling.

He W, Gong K, Smith DK, Ip NY
FEBS letters 2005 Aug 15;579(20):4317-23

---

Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.

Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H
Circulation 2003 Feb 18;107(6):798-802

---

Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.

Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H
Circulation 2003 Feb 18;107(6):798-802

Blocking/Neutralizing

Supportive validation

Submitted by

R&D Systems (provider)

Main image

Experimental details

Cell Proliferation Induced by Oncostatin M/OSM and Neutralization by Human gp130 Antibody. Recombinant Human Oncostatin M/OSM (Catalog # 295-OM) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human Oncostatin M/OSM (0.8 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human gp130 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-228-NA). The ND₅₀ is typically 2-10 µg/mL.